Intercept Pharmaceuticals Inc (ICPT) Q1 2020 earnings call dated May 11, 2020 Corporate Participants: Lisa DeFrancesco -- Vice President, Investor Relations Mark Pruzanski -- President, Chief
Intercept Pharmaceuticals Inc
-(ICPT)
XNAS:ICPT
Intercept Pharmaceuticals (NASDAQ: ICPT): Q4 2019 Earnings Snapshot
-- Intercept Pharmaceuticals (NASDAQ: ICPT) reported a fourth-quarter 2019 loss of $2.99 per share versus a loss of $2.67 per share expected.
Intercept Pharmaceuticals posts Q3 miss, stock slips
Intercept Pharmaceuticals (NASDAQ: ICPT) on Tuesday reported third-quarter results that missed Wall Street expectations, but raised its guidance for the full year.
CymaBay Therapeutics stock drops to 2-year low after bitter NASH study data
CymaBay Therapeutics (NASDAQ: CBAY) stock fell to a two-year low of $4.82 on Tuesday after disappointing nonalcoholic steatohepatitis (NASH) trial data. The
Intercept Pharmaceuticals reports mixed Q1 results
Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related to NASH
What is NASH and which biotech firms are vying for the first-mover status
NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver disorder is
Viking Therapeutics earnings preview: All eyes on NASH
Viking Therapeutics (VKTX) is scheduled to report fourth-quarter 2018 financial results on March 13, Wednesday, after the regular trading hours. The market
Intercept stock surges on positive data from liver fibrosis drug study
Intercept Pharmaceuticals (ICPT) had surged about 25% in the pre-market session on Tuesday after the biopharma company announced positive topline results from
Gilead’s credibility takes a hit on massive NASH-drug failure, rivals jump
Shares of Gilead Sciences (GILD) have tumbled 20% in the past 52 weeks on numerous reasons including weaker-than-expected quarterly results and a